The company attributed the decline primarily to lower lenalidomide sales in North America. The base business, excluding lenalidomide in North America, continued to deliver double-digit growth
The company attributed the decline primarily to lower lenalidomide sales in North America. The base business, excluding lenalidomide in North America, continued to deliver double-digit growth
<iframe src="https://hindustansphere.com/embed/cluster/6c7d2f6049567d361e90fbbeed7b53b0ea0a6d03" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Dr Reddy's Q2 profit falls 36% on lower lenalidomide sales in North America"></iframe>
